Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Bros. Advisors Lp Baker Buys 15,666 Shares of Company Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker purchased 15,666 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was acquired at an average cost of $367.71 per share, for a total transaction of $5,760,544.86. Following the completion of the purchase, the director owned 1,964,542 shares of the company’s stock, valued at approximately $722,381,738.82. This trade represents a 0.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, November 6th, Bros. Advisors Lp Baker purchased 76,140 shares of Madrigal Pharmaceuticals stock. The shares were acquired at an average price of $384.32 per share, for a total transaction of $29,262,124.80.

Madrigal Pharmaceuticals Price Performance

Shares of Madrigal Pharmaceuticals stock opened at $399.63 on Friday. The company has a fifty day moving average of $486.74 and a 200-day moving average of $497.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20. Madrigal Pharmaceuticals, Inc. has a 52-week low of $353.54 and a 52-week high of $615.00. The stock has a market capitalization of $9.23 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%. The business had revenue of $431.27 million for the quarter, compared to analysts’ expectations of $404.17 million. During the same period in the previous year, the firm posted ($5.08) EPS. Equities research analysts expect that Madrigal Pharmaceuticals, Inc. will post -3.78 EPS for the current year.

Analyst Ratings Changes

MDGL has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their target price on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research note on Wednesday. Truist Financial reiterated a “buy” rating and issued a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a research note on Wednesday. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They issued an “overweight” rating and a $685.00 price target for the company. HC Wainwright started coverage on shares of Madrigal Pharmaceuticals in a report on Wednesday. They issued a “strong-buy” rating for the company. Finally, Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $706.87.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Institutional Trading of Madrigal Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Jupiter Topco LLC acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $1,039,650,000. Paulson & CO. Inc. bought a new stake in Madrigal Pharmaceuticals in the second quarter worth $719,524,000. BlackRock Inc. bought a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth about $644,753,000. Janus Henderson Group PLC boosted its position in Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock valued at $1,051,727,000 after acquiring an additional 433,804 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new position in Madrigal Pharmaceuticals during the second quarter valued at $174,038,000. Institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.